SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G Montgomery as Strategic Corporate Advisor to the Board.

With more than three decades of experience in health care, Mr Montgomery has deep experience in start-ups (CFO and Board roles), principal investing and investment banking. In leadership roles at JPMorgan H&Q, Cowen and CSFB, he had extensive experience in public and private capital markets, M&A and partnering transactions.

Mr Montgomery currently serves as CFO of Neuvogen, a next-generation therapeutic cancer vaccine company. He is a Senior Advisor to ALTI Global, a leading global multi-family wealth management firm with approximately $70bn in assets under management. He serves on the Board of Ashvattha Therapeutics and chairs the Audit Committee too.

Mr. Montgomery also serves on the Board of the Jackson Laboratory and the Advisory Board for the Yale Cancer Center.

Raul Insa, CEO at SOM, and Silvia Panigone, Executive Chair, welcome George on board: “We are honoured to have George on board; he will help the company to move forward with the next financing and to achieve international corporate goals. He adds great value to the SOM team with his extensive experience in the corporate finance in private and public biotech and his impressive network.”

“I look forward to working with the SOM team and Board at this exciting inflection point for the company,” said Mr Montgomery “I appreciate the opportunity to work with Silvia and several of the Board members again and to make a difference for patients and their families.”